Edition:
United States

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

101.05EUR
23 Jan 2017
Change (% chg)

-- (--)
Prev Close
€101.05
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,408,499
52-wk High
€112.00
52-wk Low
€83.45

BAYGn.DE

Chart for BAYGn.DE

About

Bayer AG is a life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment is engaged in the development of prescription pharmaceuticals; contraceptives, and medical products, such as injection systems and contrast agents for diagnostic... (more)

Overall

Beta: 0.95
Market Cap(Mil.): €84,762.15
Shares Outstanding(Mil.): 826.95
Dividend: 2.50
Yield (%): 2.44

Financials

  BAYGn.DE Industry Sector
P/E (TTM): 18.79 29.51 30.38
EPS (TTM): 5.45 -- --
ROI: 8.32 15.44 14.86
ROE: 19.66 16.62 16.28

BRIEF-Bayer says Regorafenib granted priority review in Japan

* Bayer says Regorafenib from Bayer granted priority review in Japan for the second-line treatment of liver cancer Further company coverage:

Jan 20 2017

Novozymes cuts jobs, says U.S. policy, Monsanto deal pose risks

COPENHAGEN Enzymes maker Novozymes will cut 198 jobs and invest more in emerging markets, it said on Wednesday, adding it could time take to recapture past growth rates amid uncertainty over U.S. renewable energy policy and the takeover of a key partner.

Jan 18 2017

Bayer, Monsanto confirm spending plans after meeting Trump

FRANKFURT Bayer and Monsanto said on Tuesday they would spend at least half of their agriculture research and development budget in the United States over the next six years, following a meeting with President-elect Donald Trump last week.

Jan 17 2017

UPDATE 1-Bayer, Monsanto confirm spending plans after meeting Trump

* Trump elicited spending pledges from several big companies (Adds details on Bayer and Monsanto's previous R&D spending plans)

Jan 17 2017

Bayer, Monsanto pledge U.S. R&D spending, jobs after merger

FRANKFURT, Jan 17 A future combined Bayer and Monsanto expects to spend about $16 billion on research and development over the next six years with at least half of this investment made in the United States, the two companies said in a statement on Tuesday.

Jan 17 2017

BRIEF-Bayer declines comment on Trump spokesman remarks U.S. spending, jobs

* Spokesman declines comment on Trump spokesman remarks re U.S. development spending, jobs Source text for Eikon: Further company coverage:

Jan 17 2017

Bayer to boost U.S. jobs, investments amid Monsanto deal: Trump spokesman

WASHINGTON Bayer AG has pledged to boost its investments in the United States amid its deal to buy U.S. seeds giant Monsanto, investing $8 billion in research and development and adding American jobs, U.S. President-elect Donald Trump's spokesman said on Tuesday.

Jan 17 2017

Bayer to boost U.S. jobs, investments amid Monsanto deal -Trump spokesman

WASHINGTON, Jan 17 Bayer AG has pledged to boost its investments in the United States amid its deal to buy U.S. seeds giant Monsanto, investing$8 billion in research and development and adding American jobs, U.S. President-elect Donald Trump's spokesman said on Tuesday.

Jan 17 2017

Deals of the day-Mergers and acquisitions

Jan 12 The following bids, mergers, acquisitions and disposals were reported by 1100 GMT on Thursday:

Jan 12 2017

Bayer says had productive meeting with Trump over Monsanto deal

FRANKFURT German drugs and pesticides maker Bayer , which will need regulatory approval for its $66 billion deal to buy U.S. seeds giant Monsanto , said company chief executives had a productive meeting with U.S. president-elect Donald Trump.

Jan 12 2017

Earnings vs. Estimates